Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Dec;37(12):2688–2692. doi: 10.1128/aac.37.12.2688

Modulation of mucosal immunity against Campylobacter jejuni by orally administered cytokines.

S Baqar 1, N D Pacheco 1, F M Rollwagen 1
PMCID: PMC192779  PMID: 8109936

Abstract

The effect of oral recombinant interleukin (rIL) treatment on the course of Campylobacter jejuni infection and the development of mucosal immunity in mice was investigated. rIL-2, rIL-5, and rIL-6 were administered to mice at 24 and 6 h before infection and at 0, 24, and 48 h after infection with C. jejuni HC, and the subsequent development of an immune response and intestinal colonization resistance were determined. In this model, orally administered cytokines retained their biological activities with no apparent side effects. Following infection, initial bacterial counts in fecal samples collected from cytokine-treated and untreated mice were similar. However, within 48 h of infection a greater than 3-log-unit reduction in the number of C. jejuni shed in the feces was found for rIL-6-treated animals. Colonization levels were similarly reduced in rIL-5-treated mice, although the rate of clearance was somewhat slower. In contrast, rIL-2 treatment had no significant effect on colonization levels compared with that in controls. Oral rIL-6 treatment was also associated with enhanced intestinal and systemic Campylobacter-specific immunoglobulin A responses compared with those observed in either rIL-5- or rIL-2-treated animals. Upon rechallenge, initial colonization in all cytokine-treated groups was approximately 2 log units lower than that in controls. However, local infection was controlled only in rIL-2-treated mice over time. rIL-5 and rIL-6 treatment had only a marginal effect on colonization resistance following rechallenge. On the basis of these results, it appears that rIL-5 or rIL-6 may function to modulate the induction and/or expression of anti-C. jejuni immunity through different mechanisms.

Full text

PDF
2688

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bermudez L. E., Kolonoski P., Young L. S. Natural killer cell activity and macrophage-dependent inhibition of growth or killing of Mycobacterium avium complex in a mouse model. J Leukoc Biol. 1990 Feb;47(2):135–141. doi: 10.1002/jlb.47.2.135. [DOI] [PubMed] [Google Scholar]
  2. Bermudez L. E., Stevens P., Kolonoski P., Wu M., Young L. S. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol. 1989 Nov 1;143(9):2996–3000. [PubMed] [Google Scholar]
  3. Black R. E., Levine M. M., Clements M. L., Hughes T. P., Blaser M. J. Experimental Campylobacter jejuni infection in humans. J Infect Dis. 1988 Mar;157(3):472–479. doi: 10.1093/infdis/157.3.472. [DOI] [PubMed] [Google Scholar]
  4. Blanchard D. K. Cytokine activation of killer cells in mycobacterial immunity. Adv Exp Med Biol. 1992;319:105–112. doi: 10.1007/978-1-4615-3434-1_12. [DOI] [PubMed] [Google Scholar]
  5. Blaser M. J., Black R. E., Duncan D. J., Amer J. Campylobacter jejuni-specific serum antibodies are elevated in healthy Bangladeshi children. J Clin Microbiol. 1985 Feb;21(2):164–167. doi: 10.1128/jcm.21.2.164-167.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Blaser M. J., Duncan D. J., Osterholm M. T., Istre G. R., Wang W. L. Serologic study of two clusters of infection due to Campylobacter jejuni. J Infect Dis. 1983 May;147(5):820–823. doi: 10.1093/infdis/147.5.820. [DOI] [PubMed] [Google Scholar]
  7. Blaser M. J., Smith P. F., Kohler P. F. Susceptibility of Campylobacter isolates to the bactericidal activity of human serum. J Infect Dis. 1985 Feb;151(2):227–235. doi: 10.1093/infdis/151.2.227. [DOI] [PubMed] [Google Scholar]
  8. Borish L., Rosenbaum R., Albury L., Clark S. Activation of neutrophils by recombinant interleukin 6. Cell Immunol. 1989 Jul;121(2):280–289. doi: 10.1016/0008-8749(89)90026-9. [DOI] [PubMed] [Google Scholar]
  9. Burr D. H., Caldwell M. B., Bourgeois A. L., Morgan H. R., Wistar R., Jr, Walker R. I. Mucosal and systemic immunity to Campylobacter jejuni in rabbits after gastric inoculation. Infect Immun. 1988 Jan;56(1):99–105. doi: 10.1128/iai.56.1.99-105.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Caldwell M. B., Walker R. I., Stewart S. D., Rogers J. E. Simple adult rabbit model for Campylobacter jejuni enteritis. Infect Immun. 1983 Dec;42(3):1176–1182. doi: 10.1128/iai.42.3.1176-1182.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cheever M. A., Greenberg P. D. In vivo administration of interleukin-2. Contemp Top Mol Immunol. 1985;10:263–282. doi: 10.1007/978-1-4684-4838-2_11. [DOI] [PubMed] [Google Scholar]
  12. Chong K. T. Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria. Infect Immun. 1987 Mar;55(3):668–673. doi: 10.1128/iai.55.3.668-673.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cummins J. M., Rosenquist B. D. Protection of calves against rhinovirus infection by nasal secretion interferon induced by infectious bovine rhinotracheitis virus. Am J Vet Res. 1980 Feb;41(2):161–165. [PubMed] [Google Scholar]
  14. Edwards C. K., 3rd, Hedegaard H. B., Zlotnik A., Gangadharam P. R., Johnston R. B., Jr, Pabst M. J. Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma. J Immunol. 1986 Mar 1;136(5):1820–1827. [PubMed] [Google Scholar]
  15. Elson C. O., Ealding W., Lefkowitz J. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. J Immunol Methods. 1984 Feb 24;67(1):101–108. doi: 10.1016/0022-1759(84)90089-9. [DOI] [PubMed] [Google Scholar]
  16. Farrar W. L., Johnson H. M., Farrar J. J. Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol. 1981 Mar;126(3):1120–1125. [PubMed] [Google Scholar]
  17. Figlin R. A., Abi-Aad A. S., Belldegrun A., deKernion J. B. The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma. Semin Oncol. 1991 Oct;18(5 Suppl 7):102–107. [PubMed] [Google Scholar]
  18. Fleischmann W. R., Jr, Koren S., Fleischmann C. M. Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc Soc Exp Biol Med. 1992 Nov;201(2):200–207. doi: 10.3181/00379727-201-43499. [DOI] [PubMed] [Google Scholar]
  19. Garcia-Peñarrubia P., Koster F. T., Kelley R. O., McDowell T. D., Bankhurst A. D. Antibacterial activity of human natural killer cells. J Exp Med. 1989 Jan 1;169(1):99–113. doi: 10.1084/jem.169.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Garcia-Peñarrubia P., Lennon M. P., Koster F. T., Kelley R. O., Bankhurst A. D. Selective proliferation of natural killer cells among monocyte-depleted peripheral blood mononuclear cells as a result of stimulation with staphylococcal enterotoxin B. Infect Immun. 1989 Jul;57(7):2057–2065. doi: 10.1128/iai.57.7.2057-2065.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Iizawa Y., Nishi T., Kondo M., Tsuchiya K., Imada A. Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice. Infect Immun. 1988 Jan;56(1):45–50. doi: 10.1128/iai.56.1.45-50.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jeevan A., Asherson G. L. Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice. Infect Immun. 1988 Mar;56(3):660–664. doi: 10.1128/iai.56.3.660-664.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Klempner M. S., Noring R., Mier J. W., Atkins M. B. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med. 1990 Apr 5;322(14):959–965. doi: 10.1056/NEJM199004053221404. [DOI] [PubMed] [Google Scholar]
  24. Liu Z., Simpson R. J., Cheers C. Recombinant interleukin-6 protects mice against experimental bacterial infection. Infect Immun. 1992 Oct;60(10):4402–4406. doi: 10.1128/iai.60.10.4402-4406.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Maghazachi A. A. Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors. Immunology. 1990 Aug;70(4):465–472. [PMC free article] [PubMed] [Google Scholar]
  26. Matsumoto R., Matsumoto M., Mita S., Hitoshi Y., Ando M., Araki S., Yamaguchi N., Tominaga A., Takatsu K. Interleukin-5 induces maturation but not class switching of surface IgA-positive B cells into IgA-secreting cells. Immunology. 1989 Jan;66(1):32–38. [PMC free article] [PubMed] [Google Scholar]
  27. Morrissey P. J., Charrier K. Interleukin-1 administration to C3H/HeJ mice after but not prior to infection increases resistance to Salmonella typhimurium. Infect Immun. 1991 Dec;59(12):4729–4731. doi: 10.1128/iai.59.12.4729-4731.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nakano Y., Onozuka K., Terada Y., Shinomiya H., Nakano M. Protective effect of recombinant tumor necrosis factor-alpha in murine salmonellosis. J Immunol. 1990 Mar 1;144(5):1935–1941. [PubMed] [Google Scholar]
  29. Vogels M. T., van der Meer J. W. Use of immune modulators in nonspecific therapy of bacterial infections. Antimicrob Agents Chemother. 1992 Jan;36(1):1–5. doi: 10.1128/aac.36.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES